Harrow- 8.625% NT REDEEM 30/04/2026 USD 25 Profit Margin

Harrow- 8.625% NT REDEEM 30/04/2026 USD 25 (HROWL) currently reports a profit margin of -5.57% as of March 2026. That compares with -10.19% in the prior-year period — up 45.4% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Harrow- 8.625% NT REDEEM 30/04/2026 USD 25's profit margin history and peer comparisons.

Harrow- 8.625% NT REDEEM 30/04/2026 USD 25's profit margin increased from -10.19% to -5.57% — a 45.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Harrow- 8.625% NT REDEEM 30/04/2026 USD 25's profit margin of -5.57% is lower than the Healthcare sector average of 14.34%. That is roughly 138.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Harrow- 8.625% NT REDEEM 30/04/2026 USD 25's current -5.57% should be judged against Healthcare norms (sector average: 14.34%) and against HROWL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -5.57%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Harrow- 8.625% NT REDEEM 30/04/2026 USD 25, and consider following HROWL for alerts when major investors trade the stock.